Barbara Szatkowski
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 477 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by AbbVie at 47.7% of the total. Reporting peaked in 2021 at $2,934 and has fallen 97.2% since, to $82 in 2025. Among family clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 477 payments — averaging $20.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- Gilead$703
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$673
- Nestle Healthcare Nutrition Inc.$572
- Johnson & Johnson$520
- Takeda Pharmaceuticals U.S.A., Inc.$418
- plus $2K from 19 others
What the payments were for
- Food & beverage$9,46599%
- Education$991%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 215 | $4,559 |
| Gilead | 26 | $703 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 52 | $673 |
| Nestle Healthcare Nutrition Inc. | 33 | $572 |
| Johnson & Johnson | 27 | $520 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $418 |
| QOL Medical, LLC | 12 | $303 |
| Sanofi | 11 | $261 |
| Ironwood Pharmaceuticals, Inc | 13 | $199 |
| Regeneron Healthcare Solutions, Inc. | 5 | $190 |
| Merck | 8 | $148 |
| Ardelyx, Inc. | 8 | $132 |
| Aimmune Therapeutics, Inc. | 5 | $117 |
| Braintree Laboratories, Inc. | 7 | $110 |
| Daiichi Sankyo Inc. | 5 | $95 |
| Intercept Pharmaceuticals, Inc. | 5 | $95 |
| Bristol Myers Squibb | 5 | $94 |
| Ferring Pharmaceuticals Inc. | 5 | $85 |
| Janssen Scientific Affairs, LLC | 1 | $78 |
| Redhill Biopharma Inc. | 3 | $69 |
| Pfizer | 3 | $44 |
| Phathom Pharmaceuticals, Inc. | 2 | $43 |
| Organon | 1 | $21 |
| Lilly USA, LLC | 1 | $19 |
| Madrigal Pharmaceuticals | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,564 in reported general payments places this provider in the 95th percentile of 1,501 family providers in Nevada.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZenpepLipase/Protease/Amylase | 13 | $92,601 |
| LinzessLinaclotide | 54 | $41,568 |
| MotegrityPrucalopride Succinate | 16 | $14,448 |
| Dexlansoprazole DrDexlansoprazole | 31 | $10,614 |
| Colestipol Hcl | 85 | $9,334 |
| Omeprazole | 365 | $5,053 |
| Pantoprazole Sodium | 269 | $4,414 |
| Esomeprazole Magnesium | 71 | $3,855 |
| Lansoprazole | 93 | $3,223 |
| Famotidine | 179 | $2,706 |
| Sucralfate | 51 | $2,606 |
| Budesonide DrBudesonide | 25 | $2,333 |
| Dicyclomine Hcl | 94 | $2,000 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 101 | $1,614 |
| Budesonide EcBudesonide | 12 | $1,361 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Aimmune Therapeutics, Inc.Zenpep | $117 | $92,60113 claims |
| AbbVieLinzess | $4,559 | $41,56854 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $418 | $14,44816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,501 family providers in Nevada.
Other family in Reno
- Lisa Hammargren-KuykendallReno$22K
- Martha AiyukReno$15K
- Jocelyn AllenReno$12K
- Kaylie HumphreysReno$11K
- Christina KrainbrinkReno$10K
- Johanna LeeReno$9K
- Darin OldeReno$9K
- Ruth SkinnerReno$8K
- Anna EllisReno$7K
- Pauline StoltznerReno$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.